Blog

May 16, 2018

BlueBee introduces BLUEBASE, a streamlined solution transforming data into actionable knowledge for clinical and translational genomics research

RIJSWIJK, THE NETHERLANDS, May 16, 2018 — BlueBee Corporation announced today the release of BLUEBASE, a complete data management solution designed to transform next-generation sequencing (NGS) and metadata into actionable genomic knowledge with efficiency and clinical-grade security. BLUEBASE runs on the BlueBee core data analysis platform and provides post-sequencing intelligent... Read more
March 15, 2018

Data Analysis, Aggregation And Management Have an Essential Role to Play in Gaining Insights and Wisdom From Genomic Data

Precision Medicine Forum Editor Mark Glover spoke to the BlueBee’s CEO Hans Cobben (pictured) about enabling and facilitating the potential of precision medicine through data analysis. BlueBee offers an advanced global bio-informatics platform to analyse, share and store genomics data. It supports users in clinical diagnostics, pharma and research with advanced analytics... Read more
February 8, 2018

New England Biolabs and BlueBee Partner to Deliver an End-To-End Data Analysis Solution for NEBNext Direct Target Enrichment

RIJSWIJK, The Netherlands & Ipswich, Massachusetts, USA — February 8, 2018 – BlueBee, a company driving global genomic data-driven medicine, and New England Biolabs, Inc. (NEB®) have partnered to provide a secure and convenient data processing solution for NEB’s NEBNext Direct target enrichment technology. Through this partnership, BlueBee enables NEB’s... Read more
December 19, 2017

Agendia and BlueBee Partner to Bring New NGS-Based MammaPrint® BluePrint® Breast Cancer Kit to Market

RIJSWIJK, NETHERLANDS and IRVINE, CA, AMSTERDAM, – 19 December 2017 – BlueBee, a company driving global genomic data-driven medicine, and Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, have partnered to provide a secure, convenient, data processing solution for Agendia’s MammaPrint BluePrint Breast Cancer Recurrence and... Read more
December 7, 2017

BlueBee adds NEN 7510:2011 Certification to its Security Portfolio

Read more
November 16, 2017

SLAMdunk – Another Optimized Lexogen, BlueBee Pipeline to Simplify Data Analysis

In September this year, Lexogen released the family of SLAMseq Metabolic RNA labeling kits, the underlying methodology of which is based on S4U labeling of RNA in cell cultures, alkylation of RNA with iodoacetamide, and the consequent introduction of T to C mutations in cDNA. To simplify the data analysis component... Read more
November 10, 2017

Lexogen and BlueBee Partner to Bring the SLAMseq Metabolic RNA Sequencing Data Analysis Pipeline to the Users

RIJSWIJK, The Netherlands and Vienna, Austria — November 10, 2017 — BlueBee, a company driving genomic data-driven medicine, and Lexogen a company enabling the analysis of the complete transcriptome, announce the successful integration of the SLAMdunk pipeline on BlueBee’s private cloud-based platform, making it available to analyze data generated by every... Read more
November 6, 2017

Overcoming High Sequence Complexity with the PacBio De Novo Assembly Pipeline, on the BlueBee Platform

Complex elements – repetitive regions, copy number variants, or structural variations – are challenging, if not impossible to sequence using short-read technologies. PacBio’s long-read technology based on Single Molecule, Real-Time (SMRT) sequencing, delivers long reads with uniform coverage, allowing comprehensive de novo genome assemblies that can overcome the short-read sequencing... Read more
November 3, 2017

ASHG 2017 was all About Expediting the Analysis and Interpretation of Research and Clinical Data

The theme of this year’s annual gathering of geneticists at the American Society of Human Genetics conference held in Orlando was centered around expediting the analysis and interpretation of both research and clinical data. The conference kicked off with a talk by ASHG President Dr. Nancy Cox, highlighting the need for... Read more
October 9, 2017

PACBIO AND BLUEBEE LAUNCH DE NOVO GENOME ASSEMBLY PIPELINE ON THE BLUEBEE ANALYSIS PLATFORM

RIJSWIJK, The Netherlands and MENLO PARK, Calif., — October 9th, 2017 — BlueBee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ:PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the BlueBee® genomics analysis platform. The integration creates... Read more
Request A Demo